30 results about "Anti-angiogenic drugs" patented technology

The invention relates to a somatostatin receptor-mediated tumor targeted pharmaceutical composition which adopts a targeted somatostatin receptor functional polypeptide and polyethylene glycol for simultaneously modifying a pharmaceutical carrier, and an anti-tumor drug or/and an anti-angiogenic drug is delivered to the tumor part, thereby enhancing the tumor treatment effect.

A method is provided that allows a subject to be diagnosed as having one of a variety of hypertensive states, including pre-eclampsia, based on the measurement of a plurality of factors including the level of soluble fms-like tyrosine kinase 1 (sFlt-1), an obesity factor and optionally one or more additional factors, which may be physiological parameters or biomarkers. The method can be used to determine hypertensive states associated with pregnancy, or associated with anti-angiogenic drug therapy. The method is thus useful for diagnosing the hypertensive status of pregnant women, as well as patients undergoing anti-angiogenic treatment (e.g., chemotherapy).

The invention provides the application of tetracyclic triterpenoids compound cucurbitacins E in preparing anti-angiogenic drugs. The cucurbitacins E can inhibit tumor angiogenesis, arthritis pathological tissue vessel angiogenesis, neovascular eye disease, hemangioma pathological tissue angiogenesis, psoriasis pathological tissue vessel angiogenesis, solid tumor pathological tissue angiogenesis, hemangioma, Kaposi' s sarcoma pathological tissue angiogenesis, leukocythemia, lymphadenoma, myeloma blood cancer and Paget' s disease angiogenesis. The invention also provides the application of a compound containing effective dose of cucurbitacins E and pharmacy acceptable ingredients in preparing the anti-angiogenic drugs.

The invention provides an application of osthole in preparing anti-angiogenic drugs. The osthole can inhibit tumor angiogenesis, arthritis pathological tissue vessel angiogenesis, neovascular eye disease, hemangioma pathological tissue angiogenesis, psoriasis pathological tissue vessel angiogenesis, solid tumor pathological tissue angiogenesis, hemangioma, Kaposi's sarcoma pathological tissue angiogenesis, leukocythemia, lymphadenoma, myeloma blood cancer and Paget's disease angiogenesis. The invention also provides the application of a compound containing effective dose of osthole and pharmacy acceptable ingredients in preparing the anti-angiogenic drugs.

A method for modulating at least one pharmacokinetic property of an anti-angiogenic or blood disease or steroid therapeutic and efficacy upon administration to a host is provided. One administers to the host an effective amount of a bifunctional compound of less than about 5000 Daltons comprising the anti-angiogenic or blood disease or steroid therapeutic or an active derivative thereof and a pharmacokinetic modulating moiety. The pharmacokinetic modulating moiety binds to at least one intracellular protein. The bifunctional compound has at least one modulated pharmacokinetic property upon administration to the host as compared to a free drug control that comprises the anticancer therapeutic as well as enhanced efficacy not due to compound degradation. It is preferred that the pharmacokinetic modulating moiety has a mass of less than 1100 Daltons.

The invention relates to an application of a beta 3-endoxine protein factor as a target molecule in regulation of neovascularization. When expression of beta 3-endoxine in vascular endothelial cells is down-regulated or small-molecule polypeptide compounds capable of being bound with beta 3-endoxine are used for acting on the vascular endothelial cells, expression of a VEGF (vascular endothelial growth factor) can be effectively inhibited, and proliferation of the vascular endothelial cells and the capacity of forming vascular-like structures by the vascular endothelial cells can also be reduced. Therefore, the beta 3-endoxine protein factor expressed by the vascular endothelial cells is an effective target for developing anti-angiogenic drugs, and two effective anti-angiogenic methods areprovided on the basis of the factor.

The invention provides an application of anacardic acid in preparing anti-angiogenic drugs. The anti-angiogenic drugs prepared from anacardic acid of the invention can inhibit tumor angiogenesis, arthritis pathological tissue vessel angiogenesis, neovascular eye disease, hemangioma pathological tissue angiogenesis, psoriasis pathological tissue vessel angiogenesis, solid tumor pathological tissueangiogenesis, hemangioma, Kaposi' s sarcoma pathological tissue angiogenesis, leukocythemia, lymphadenoma, myeloma blood cancer and Paget' s disease angiogenesis. The invention also provides the application of a compound containing effective dose of anacardic acid and pharmacy acceptable ingredients in preparing the anti-angiogenic drugs.

Methods for selecting whether to administer an anti-angiogenic therapeutic agent to a subject include steps of measuring the expression levels of one or more biomarkers selected from Table 2 or Table 3 in a sample from the subject; assessing from the expression levels of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated. Related prognostic methods and treatment methods are also provided. The invention is particularly applicable in ovarian and colorectal cancers.

The invention relates to a sulfation derivative of dendrobium stem polysaccharide and a preparation method and application of the sulfation derivative. Dendrobium stem polysaccharide is shown as the following structural formula. In-vitro and in-vivo experimental studies indicate that the sulfation derivative of dendrobium stem polysaccharide has the anti-angiogenic drug activity.

The invention provides daun negokilo polysaccharide and application thereof in preparation of immunoregulatory and antineoplastic drug and functional food. The daun negokilo polysaccharide can promote mononuclear macrophage strain to devour neutral red and release nitric oxide, can promote proliferation of cell B and cell T, can remarkably improve spleen and thymus indexes of immunosuppressed mice, transformation and proliferation of the cell T and the cell B and leucocyte level of the immunosuppressed mice, can obviously inhibit growing of tumor tissue and can protect organism, inhibit lowering of body weight and increase body weight. Polysaccharide serves as a main functional component, has multiple healthcare functions, is purely natural in source, thereby being free of side effect, and can be developed to be immunoregulatory, antineoplastic and anti-angiogenic drug and healthcare products, thereby having good market application prospect.

An oligopeptide isolated from an SCO-spondin glycoprotein, characterized by the sequence: —W—S—X₁—W—S— X₂—C—S— X₃—X₄—C-G- (SEQ ID NO: 1), in which X₁, X₂, X₃ and X₄ represent amino acid sequences that consist of 1 to 5 amino acids. The oligopeptide may be used as a drug for inhibiting angiogenesis, in the treatment of diseases associated with angiogenesis in humans or animals, in particular against tumor angiogenesis. The oligopeptide is suitable in particular for the treatment of brain tumors.

The invention relates to a gambogic acid ester derivative as well as a preparation method and a use thereof. The structural formula of the derivative is as shown in formula (I) in the specification. The preparation method of the gambogic acid ester derivative comprises the following steps of: dissolving gambogic acid, gemcitabine and triphenylphosphine in anhydrous tetrahydrofuran under the protection of nitrogen gas; injecting a THF (Tetrahydrofuran) solution containing Diethyl Azodicarboxylate (DEAD) and reacting for 12-24 hours; and obtaining a product by washing, drying, rotary steaming and column chromatography. The derivative can be used for preparing a composition, an antineoplastic drug, an antifungal drug or an anti-angiogenic drug or is combined with other anti-cancer active components. The derivative disclosed by the invention not only has good activity to a plurality of tumor cells, but also has good targeting performance to the tumor cells, and therefore, a foundation is laid for developing novel drugs.

The invention provides an application of an EGFR (epidermal growth factor receptor) inhibitor and an anti-angiogenesis medicine in a medicine for treating tumor diseases. Specifically, the invention provides an application of a human epidermal growth factor receptor inhibitor (EGFRi) combined anti-angiogenesis medicine in a medicine for preventing or treating tumor diseases.

The invention relates to an anti-angiogenic compound and usage thereof. A generative model of zebra fish blood vessels is used for carrying out an internal pharmacodynamic experiment confirmation. The compound can obviously restrain the blood vessels angiogenesis of the zebra fish. Therefore, the compound can be used for preparing the anti-angiogenic drugs, anti-tumor effect drugs and senile macular degeneration drugs.